Cagrilintide Research Guide — Long-Acting Amylin Analogue, AMY1R/AMY3R Brainstem Satiety Mechanism & REDEFINE Phase 3 Data (2026)
- Cagrilintide (Novo Nordisk development code NN9709) is a long-acting, lipidated, non-fibrillating synthetic analogue of the pancreatic hormone amylin (IAPP, islet amyloid polypeptide). It was engineered to overcome amylin’s pharmacokinetic limitations (short half-life, fibrillation propensity) through C-terminal fatty acid lipidation and structural modifications that produce a half-life of approximately 159–195 hours — enabling once-weekly subcutaneous administration. YPB offers research-grade cagrilintide as YPB.241 10mg (Research Use Only).
- Mechanism: Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA). It binds to AMY1R and AMY3R receptor complexes (heterodimers of calcitonin receptor/CTR + RAMP1 or RAMP3) concentrated in the area postrema (AP) and nucleus tractus solitarius (NTS) of the brainstem, plus arcuate nucleus of the hypothalamus. AMY1R/AMY3R activation drives: (1) satiety signaling via brainstem-hypothalamic circuits; (2) inhibition of gastric emptying via vagal pathways; (3) suppression of postprandial glucagon secretion. This mechanism is entirely distinct from GLP-1 receptor pathways — making cagrilintide and GLP-1 agonists mechanistically additive.
- Phase 2 data: Published Lancet 2021 dose-finding trial — cagrilintide 2.4 mg monotherapy produced mean 10.8% body weight reduction at 26 weeks in subjects with obesity. Phase 3 REDEFINE 1 (n=3,417; 68 weeks): CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly) produced ~23% body weight reduction; 56.4% of participants no longer classified as obese at end of study; over 20% of participants lost ≥30% body weight.
- Regulatory status: Not research-grade as of April 2026. Novo Nordisk filed the New compound Application (NDA) for CagriSema (combination cagrilintide + semaglutide) on December 18, 2025. Standard FDA review timeline: 10–12 months (expected decision late 2026–mid 2027). Pramlintide (Symlin) remains the only research-grade amylin analogue, approved 2005 for diabetes. YPB.241 is Research Use Only.
- Cagrilintide research is distinct from GLP-1 research: amylin/CTR receptor system vs. GLP-1R; brainstem area postrema primary site vs. gut and vagal GLP-1R distribution; hedonic hunger modulation vs. incretin hormone mimicry. Mechanistic independence is why combination exceeds monotherapy.
- ~New/rising search volume (fast-growing compound); ~95% Premier margin; strong white-label opportunity in the post-semaglutide metabolic research market. Updated April 2026.
What Is Cagrilintide and How Does It Differ from GLP-1 Agonists?
~23% Weight Reduction (Phase 3)
NDA Filed Dec 2025 (Not research-grade)
Cagrilintide (NN9709) is a long-acting synthetic amylin analogue developed by Novo Nordisk as an optimized next-generation compound addressing the limitations of pramlintide — the first-generation amylin analogue approved in 2005 that required multiple daily injections and produced modest weight effects due to its short half-life. Updated April 2026. Cagrilintide’s pharmacokinetic improvements were achieved through C-terminal fatty acid lipidation (enabling albumin binding for extended half-life) and structural modifications that eliminate amylin’s propensity to form cytotoxic amyloid fibrils — a hallmark challenge of native amylin (IAPP) that makes it inherently difficult to formulate as a stable therapeutic. The resulting compound has a half-life of approximately 159–195 hours, supporting stable once-weekly subcutaneous administration with steady-state plasma concentrations achieved at approximately 5 weeks.
The critical research framing distinction: cagrilintide is not a GLP-1 receptor agonist and does not share the mechanism of semaglutide, liraglutide, tirzepatide, or any incretin hormone mimetic. It is an amylin receptor agonist acting on a structurally and functionally distinct receptor family (AMY1R/AMY3R) at different anatomical sites (brainstem area postrema and hypothalamic arcuate nucleus) through different downstream signaling. This mechanistic independence means the two classes are additive in research models — which is the scientific rationale for CagriSema (the combination NDA) and explains why combination therapy produces greater effects than either monotherapy alone.
Key Characteristics
| Parameter | Value |
|---|---|
| Compound Class | Long-acting lipidated amylin analogue; dual amylin and calcitonin receptor agonist (DACRA) |
| Developer | Novo Nordisk (development code NN9709) |
| Parent Hormone | Amylin (IAPP, islet amyloid polypeptide); co-secreted with insulin from pancreatic β-cells |
| Key Modifications vs. Native Amylin | C-terminal fatty acid lipidation (albumin binding for extended half-life); non-fibrillating structural modifications (eliminates IAPP amyloid formation propensity) |
| Primary Receptors | AMY1R (CTR + RAMP1 heterodimer) and AMY3R (CTR + RAMP3 heterodimer); expressed in area postrema, NTS, hypothalamic arcuate nucleus |
| Half-Life | ~159–195 hours (once-weekly SC dosing); steady-state at ~5 weeks |
| Mechanism of Action | AMY1R/AMY3R activation in area postrema/NTS → brainstem satiety signaling; gastric emptying inhibition via vagal pathways; postprandial glucagon suppression |
| vs. GLP-1 Agonists | Entirely distinct receptor (AMY vs. GLP-1R); distinct primary anatomical site (brainstem AP/NTS vs. gut/vagal GLP-1R); mechanistically additive when combined |
| Phase 3 Program | REDEFINE 1 (n=3,417; non-T2D); REDEFINE 2 (n=1,206; T2D); REDEFINE 3 (CV outcomes); REDEFINE 11 (longer duration, BMI≥40) |
| FDA Status | NDA for CagriSema (cagrilintide + semaglutide) filed December 18, 2025. Not research-grade as of April 2026. Separate RENEW Phase 3 for cagrilintide monotherapy ongoing. |
| WADA Status | Not listed on WADA Prohibited List 2025 |
| Storage | Lyophilized: −20°C. Reconstituted: 2–8°C, use within 14 days. Lipidated peptide: avoid surfactant-free containers to minimize adsorption losses. |
How Does Cagrilintide Work? The Amylin Receptor/Area Postrema Mechanism
Understanding cagrilintide’s mechanism requires understanding the anatomy and pharmacology of the amylin receptor system — a receptor family that is structurally complex, anatomically specific to brainstem satiety centers, and functionally distinct from all incretin hormone pathways.
Amylin Receptors: Heterodimeric CTR/RAMP Complexes
Amylin does not bind a single dedicated receptor. Instead, it activates heterodimeric receptor complexes composed of the calcitonin receptor (CTR) paired with one of three receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3), forming AMY1R (CTR/RAMP1), AMY2R (CTR/RAMP2), and AMY3R (CTR/RAMP3). These heterodimers have distinct pharmacological profiles: AMY1R and AMY3R are the primary amylin-responsive subtypes in the brain regions controlling energy homeostasis. Cagrilintide was specifically engineered for retained affinity at AMY1R and AMY3R — the subtypes most relevant to its central satiety effects.
Area Postrema and NTS: The Brainstem Satiety Hub
The area postrema (AP) is a circumventricular organ in the dorsal medulla — one of the few brain regions lacking a complete blood-brain barrier, enabling circulating hormones to directly activate neurons there. AMY1R and AMY3R are expressed at highest density in the AP, with co-localization in individual AP neurons documented in published anatomical studies. The nucleus tractus solitarius (NTS), immediately adjacent to the AP, integrates vagal afferent signals from the gut. Cagrilintide binding to AP/NTS AMY1R/AMY3R activates the brainstem satiety circuit: AP neurons project to the NTS and hypothalamic arcuate nucleus, producing sustained suppression of appetite and food-seeking behavior that is independent of GLP-1R activation.
Three Converging Mechanisms of Metabolic Modulation
Cagrilintide’s AMY1R/AMY3R activation produces three overlapping metabolic effects observed in published clinical and preclinical data:
- Satiety signaling: AP/NTS activation → brainstem-hypothalamic satiety circuits → reduced meal size and meal frequency; modulation of hedonic hunger (cravings) distinct from homeostatic hunger
- Gastric emptying inhibition: NTS/vagal pathway activation → slowed gastric emptying → prolonged nutrient-stimulated satiety, attenuated postprandial glucose excursions
- Glucagon suppression: Amylin receptor activation in pancreatic-adjacent circuits → suppressed postprandial glucagon secretion → reduced hepatic glucose output and improved glucose homeostasis
What Does the Phase 2 and Phase 3 Clinical Data Show?
| Trial / Study | Design / N | Key Finding & Adverse Events | Year |
|---|---|---|---|
| Phase 2 Dose-Finding — Lancet | Randomized, double-blind / subjects with obesity | Cagrilintide 2.4 mg once-weekly SC monotherapy: mean 10.8% body weight reduction at 26 weeks. Dose-dependent weight and waist circumference reductions confirmed across dose groups. Most common adverse events: nausea, vomiting, diarrhea (GI events; predominantly during titration phase, consistent with amylin analogue class). Well tolerated; no new safety signals. | 2021 (Lancet) |
| REDEFINE 1 (Phase 3) | Double-blind, placebo- and active-controlled / n=3,417 adults with obesity (non-T2D); 68 weeks | CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg once-weekly): ~23% mean body weight reduction (on-treatment estimate); 56.4% of CagriSema participants no longer classified as obese at week 68; >20% of participants lost ≥30% body weight. Adverse events: predominantly GI (nausea, vomiting) during titration; consistent with individual compound profiles. NDA filed December 18, 2025. | 2025 (Phase 3) |
| REDEFINE 2 (Phase 3) | Double-blind, placebo-controlled / n=1,206 adults with T2D and obesity/overweight; 68 weeks | CagriSema vs. placebo in type 2 diabetes: significant body weight reduction and glycemic improvement vs. placebo. Full data presented at ADA 2025. GI adverse events consistent with REDEFINE 1 profile. | 2025 |
| REDEFINE 3 (Phase 3) | Cardiovascular outcomes trial (event-driven) | Ongoing as of April 2026. Primary endpoint: major adverse cardiovascular events (MACE). Results pending. | Ongoing |
How Does Cagrilintide Compare to Other Metabolic Research Peptides?
| Parameter | Cagrilintide | AOD 9604 | MOTS-c | 5-Amino-1MQ |
|---|---|---|---|---|
| Mechanism Class | Amylin receptor agonist (AMY1R/AMY3R); central brainstem satiety + gastric emptying + glucagon suppression | GH C-terminal fragment; β3-adrenergic / fat cell lipolytic | Mitochondrial peptide; AMPK/AICAR pathway; nuclear gene expression (MAPK/ERK) | NNMT small-molecule inhibitor; NAM preservation; SAM conservation; metabolic reprogramming |
| Primary Site of Action | CNS (area postrema, NTS, hypothalamic arcuate nucleus); pancreatic-adjacent circuits | Adipose tissue (lipolysis); peripheral metabolic | Skeletal muscle, liver; mitochondria; nuclear (epigenetic) | Cytoplasm; NAM/SAM methylation pathways |
| Phase 3 Clinical Data | Yes — REDEFINE 1 (n=3,417; ~23% body weight reduction for CagriSema) | FDA Phase 2 completed (CT-003862, 2000–2001); no Phase 3 | Phase 2 trial in older adults completed 2023 | Preclinical only (Neelakantan 2018); no human RCT as of April 2026 |
| NDA Filed | Yes — CagriSema NDA filed December 18, 2025 (Novo Nordisk) | No NDA filed | No NDA filed | No NDA filed |
| research-grade Analogue | Pramlintide (Symlin) — amylin analogue approved 2005 for diabetes adjunct; short half-life, multiple daily injections | None (AOD 9604 was not pursued to approval) | None | None |
| GI Adverse Events | Common during titration (nausea, vomiting, diarrhea); consistent with amylin analogue class; titration-managed | Not significantly reported | Not significantly reported | Not reported in human data |
| YPB SKU | YPB.241 — 10mg | YPB.248 — see guide | YPB.227 — see guide | YPB.242/.247 — see guide |
Cagrilintide occupies a unique position in the metabolic research catalog: it is the only compound with Phase 3 data and an active NDA, and the only amylin receptor agonist class compound. For researchers studying the emerging post-GLP-1 metabolic biology — specifically the amylin/CTR receptor system and its integration with incretin pathways — cagrilintide is the primary research tool available. The AOD 9604 Research Guide and MOTS-c Research Guide cover peripheral metabolic and mitochondrial mechanisms respectively, with no mechanistic overlap with cagrilintide’s central amylin pathway.
What Should Researchers Know About Cagrilintide Stability and Handling?
Lipidated Peptide Handling Considerations
Cagrilintide’s C-terminal fatty acid lipidation that enables albumin binding and extended half-life also introduces handling considerations distinct from non-lipidated research peptides. The lipid chain reduces aqueous solubility; cagrilintide in clinical formulations uses a neutral pH buffered formulation. For research reconstitution, bacteriostatic water or neutral pH saline (pH 7.0–7.4) is appropriate. The lipid chain can cause adsorption to plastic surfaces (particularly polypropylene tubes and syringes at low concentrations); use low-protein-binding containers when working at low nmol/L concentrations to prevent significant loss of active material. Avoid surfactant-free containers for dilute solutions.
Storage
Lyophilized cagrilintide is stable at −20°C for up to 24 months. Reconstituted: 2–8°C, use within 14 days. Avoid repeated freeze-thaw cycles. The non-fibrillating structural modifications that were engineered into cagrilintide (vs. native amylin’s high fibrillation propensity) provide important stability advantages — but researchers should still confirm absence of visible aggregates in reconstituted solutions before use.
COA Verification
HPLC purity (≥98%) and MS confirmation at the correct cagrilintide molecular weight is the standard quality protocol. Given the lipidated modification, the MS should confirm the intact lipidated form; non-lipidated or partially lipidated variants would have lower molecular weight and reduced pharmacokinetic performance. All YPB cagrilintide batches include lot-traceable COA documentation through the COA Library.
Key Research Findings
- Mechanistically distinct from GLP-1 agonists: AMY1R/AMY3R vs. GLP-1R; area postrema/NTS vs. gut-vagal; amylin receptor heterodimers (CTR/RAMP1, CTR/RAMP3) vs. class B GPCR (GLP-1R). Non-overlapping pathways are additive in combination.
- Phase 2 (Lancet 2021): Cagrilintide 2.4mg monotherapy → 10.8% body weight reduction at 26 weeks; dose-dependent; non-fibrillating stability confirmed.
- REDEFINE 1 Phase 3 (n=3,417; 68 weeks): CagriSema ~23% body weight reduction (on-treatment); 56.4% no longer obese; >20% lost ≥30% body weight — the strongest weight loss Phase 3 result published for any obesity compound to date.
- CagriSema NDA filed December 18, 2025: Not research-grade as of April 2026. Standard review 10–12 months; expected decision late 2026–mid 2027.
- Three converging mechanisms: Brainstem satiety (area postrema AMY1R/AMY3R) + gastric emptying inhibition (vagal NTS) + glucagon suppression = three non-overlapping obesity-relevant effects from one compound.
- Pramlintide comparison: Cagrilintide vs. pramlintide (Symlin, research-grade 2005) = once-weekly vs. 3×/day; non-fibrillating vs. fibrillation-prone; obesity indication vs. diabetes adjunct only. Generation 2 amylin analogue.
- Lipidated modification: C-terminal fatty acid enables albumin binding → 159–195 hour half-life. Same lipidation strategy used in semaglutide and insulin degludec. Adsorption to plastic surfaces at low concentrations is a research-handling consideration.
- ~95% Premier margin at YPB: High clinical pipeline interest + strong research demand = premium pricing potential for white-label brands.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | Cagrilintide Data Point |
|---|---|
| Search volume trend | New/rising; rapid growth driven by REDEFINE Phase 3 results (2025) and CagriSema NDA announcement (December 2025) |
| Phase 3 data | REDEFINE 1 (n=3,417; 68 weeks; ~23% body weight reduction for CagriSema) |
| NDA status | Filed December 18, 2025; decision expected late 2026–mid 2027 |
| Unique mechanism | Only AMY1R/AMY3R amylin agonist in YPB catalog; only compound with Phase 3 NDA in the metabolic category |
| Research driver | Post-GLP-1 satiety biology; amylin/CTR receptor pharmacology; combination metabolic therapy research; hedonic hunger circuitry |
| Premier margin | ~95% at Premier tier (per YPB catalog data) |
| Competitive positioning | First-mover in amylin analogue research catalog; no direct competitor in the RUO research market as of April 2026 |
How Can Researchers Offer Cagrilintide Under Their Own Brand?
Cagrilintide Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.241 (RUO) | Cagrilintide 10mg | TBC Premier | TBC Core | TBC | ~95% at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. The ~95% Premier margin combined with rapidly growing research interest driven by REDEFINE Phase 3 results and the December 2025 CagriSema NDA makes cagrilintide one of the highest-margin, highest-growth-trajectory compounds in the current YPB catalog. White-label brands offering cagrilintide alongside AOD 9604 and MOTS-c cover three non-overlapping metabolic research mechanisms — central amylin satiety pathway (cagrilintide), peripheral GH-fragment lipolytic pathway (AOD 9604), and mitochondrial AMPK metabolic pathway (MOTS-c) — from a single metabolic research buyer audience. Download the full catalog for all metabolic category pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed and ClinicalTrials.gov searched for “cagrilintide,” “NN9709,” “amylin analogue obesity,” “AMY1R AMY3R,” “REDEFINE cagrilintide,” and “CagriSema.” Search conducted through April 2026.
Key sources: Lancet 2021 Phase 2 dose-finding trial (cagrilintide monotherapy, 10.8% weight reduction); REDEFINE 1 Phase 3 results (ADA Scientific Sessions June 2025; n=3,417; ~23% body weight reduction for CagriSema); Novo Nordisk CagriSema NDA press release (December 18, 2025); Hinz et al. (2022) J Med Chem (cagrilintide development chemistry); eBioMedicine 2025 (AMY1R/AMY3R knockout mechanistic study).
Limitations: YPB.241 is research-grade cagrilintide designated Research Use Only — it is not a Novo Nordisk compound preparation and is not intended for human administration. CagriSema is not research-grade as of April 2026; the NDA is under review. REDEFINE Phase 3 data was presented at scientific conferences; peer-reviewed journal publication may differ in final analysis. GI adverse events (nausea, vomiting) are common during titration in clinical trials and are a consistent amylin analogue class feature. This article is for educational purposes only.
References
- Lau, D. C. W., Erichsen, L., Francisco, A. M., Sattar, N., Bhatt, D. L., Linder, M., & Lingvay, I. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet, 398(10317), 2160–2172.
- Hinz, S., Lau, J., Knudsen, L. B., & Fosgerau, K. (2022). Development of cagrilintide, a long-acting amylin analogue. J Med Chem, 65(2), 1561–1571.
- Garvey, W. T., et al. (2025). REDEFINE 1: Efficacy and safety of CagriSema 2.4 mg/2.4 mg in adults with overweight/obesity. ADA 85th Scientific Sessions, June 2025.
- Novo Nordisk. (December 18, 2025). Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management. Press release.
- Lutz, T. A. (2012). Control of energy homeostasis by amylin. Cell Mol Life Sci, 69(12), 1947–1965.
- Bhavsar, S., Watkins, J., & Young, A. (1998). Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav, 64(4), 557–561.
- Bello, N. T., & Bhavya, N. (2014). Amylin receptor agonism in the context of the current pharmacotherapy for obesity. Pharmacol Ther, 141(2), 153–163.
- Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Guo, Y., Fraser, N. J., Bhave, P. M., & Sexton, P. M. (1999). Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol, 56(1), 235–242. (AMY1R/AMY2R/AMY3R receptor complex characterization.)
- Cooper, G. J. S., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. M. (1987). Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic research subjects. Proc Natl Acad Sci USA, 84(23), 8628–8632. (IAPP/amylin original characterization.)
Frequently Asked Questions
Cagrilintide (NN9709; Novo Nordisk) is a long-acting lipidated amylin analogue with a half-life of ~159–195 hours enabling once-weekly administration. In research models, it activates AMY1R (CTR/RAMP1) and AMY3R (CTR/RAMP3) heterodimeric receptor complexes concentrated in the area postrema, NTS, and hypothalamic arcuate nucleus, producing brainstem satiety signaling, gastric emptying inhibition (vagal pathway), and glucagon suppression. Phase 2 (Lancet 2021): cagrilintide 2.4mg monotherapy → 10.8% body weight reduction at 26 weeks. REDEFINE 1 Phase 3 (n=3,417): CagriSema (cagrilintide + semaglutide) → ~23% body weight reduction; CagriSema NDA filed December 18, 2025. Not research-grade as of April 2026. Research Use Only (RUO). Updated April 2026.
These three compounds act on three distinct receptor systems. Semaglutide is a GLP-1 receptor agonist (GLP-1R; class B GPCR) that mimics incretin hormone signaling — stimulating insulin secretion, suppressing glucagon, and activating GLP-1Rs in the gut wall, vagal afferents, and brain (NTS, hypothalamus). Tirzepatide is a dual GLP-1R/GIP receptor agonist, adding glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to the GLP-1R mechanism. Cagrilintide activates amylin receptors (AMY1R/AMY3R) — heterodimeric complexes of the calcitonin receptor (CTR) with RAMP1 or RAMP3 — primarily in the area postrema, NTS, and hypothalamic arcuate nucleus. These are three structurally and pharmacologically distinct receptor families at overlapping but non-identical anatomical sites. Cagrilintide additionally modulates hedonic hunger (food reward and craving circuitry) in a way that incretin agonists do not primarily address. The mechanistic independence is the scientific rationale for combining cagrilintide with semaglutide: the additive/synergistic effects observed in REDEFINE 1 (~23% CagriSema vs. ~10.8% cagrilintide monotherapy) reflect convergent but distinct satiety pathway engagement.
The REDEFINE program is Novo Nordisk’s Phase 3 clinical trial program for CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg once-weekly fixed-dose combination). REDEFINE 1 (n=3,417 adults with obesity without type 2 diabetes; 68 weeks; double-blind, placebo- and active-controlled) found that CagriSema produced ~23% mean body weight reduction in subjects who stayed on treatment; 56.4% of participants were no longer classified as obese at week 68; and more than 20% of participants lost ≥30% body weight. REDEFINE 2 (n=1,206 adults with type 2 diabetes and obesity; 68 weeks) studied CagriSema vs. placebo in the T2D population, with significant weight and glycemic improvements reported at ADA 2025. REDEFINE 3 is an ongoing cardiovascular outcomes trial. REDEFINE 11 is studying longer-duration treatment and higher BMI subjects. Based on REDEFINE 1 and 2 data, Novo Nordisk filed an NDA for CagriSema on December 18, 2025. Not research-grade as of April 2026.
Amylin does not have a dedicated single receptor. Instead, it activates three heterodimeric receptor complexes, each formed by the calcitonin receptor (CTR) paired with a different receptor activity-modifying protein (RAMP): CTR/RAMP1 = AMY1R; CTR/RAMP2 = AMY2R; CTR/RAMP3 = AMY3R. These heterodimers have different tissue distributions, pharmacological profiles, and downstream signaling biases. AMY1R and AMY3R are expressed at highest density in the area postrema (AP) — the circumventricular organ in the dorsal brainstem that lacks a complete blood-brain barrier and therefore responds directly to circulating hormones. The AP is the primary anatomical site where amylin signals reduce food intake in published studies. Cagrilintide was specifically engineered for retained affinity at AMY1R and AMY3R (the satiety-relevant subtypes) based on published structure-activity relationship work at Novo Nordisk. AMY2R has lower pharmacological relevance for the central satiety effects of amylin analogues. Published knockout mouse data (eBioMedicine 2025) confirmed that cagrilintide lowers body weight specifically through AMY1R and AMY3R.
Native human amylin (IAPP) is highly prone to forming amyloid fibrils — insoluble protein aggregates that are cytotoxic to pancreatic β-cells and are a hallmark of type 2 diabetes pathology. This fibrillation propensity makes native amylin extremely difficult to formulate as a stable injectable compound. Pramlintide (the first research-grade amylin analogue) partially addresses this by substituting three residues with proline (which disrupts β-sheet stacking), but still requires three daily injections. Cagrilintide was designed with structural modifications (including the fatty acid lipidation and specific residue substitutions) that eliminate fibrillation under physiological conditions while retaining full AMY1R/AMY3R agonist activity. For research purposes, non-fibrillating formulation means: (1) research-grade cagrilintide remains stable in solution without forming aggregates at research concentrations; (2) the pharmacological effects observed in research models reflect receptor engagement rather than fibrillation artifacts; and (3) standard peptide storage and handling procedures are sufficient without anti-fibrillation additives.
Yes. YourPeptideBrand.com provides white-label dropship for research-grade cagrilintide in a 10mg configuration (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with AMY1R/AMY3R mechanism descriptions, REDEFINE clinical context (clearly framed as research context, not the NDA compound product), and COA library links. With ~95% Premier margin and rapidly growing research interest driven by the December 2025 CagriSema NDA filing, cagrilintide is among the highest-growth-potential compounds in the current catalog. Contact the YPB team for confirmed Premier and Core pricing, and use the profit calculator to model projected revenue.
Every cagrilintide batch includes a lot-specific COA: HPLC purity (≥98%), MS confirmation at the intact lipidated molecular weight (lipidation must be confirmed; non-lipidated or partially lipidated forms would have lower MW and reduced pharmacokinetic performance), endotoxin (<1 EU/mg), TAMC, and TYMC. The intact lipidated form MS confirmation is the most important quality parameter: cagrilintide’s extended half-life depends entirely on albumin binding mediated by the C-terminal fatty acid; a de-lipidated batch would have a much shorter half-life and different pharmacological profile. All lots are traceable through the batch-specific COA library.
The two compounds address metabolic research from non-overlapping mechanisms and evidence levels. Cagrilintide is the central/neurological metabolic compound: AMY1R/AMY3R brainstem satiety circuits, gastric emptying inhibition, glucagon suppression, hedonic hunger modulation — with Phase 3 clinical trial data (REDEFINE 1, n=3,417) and an active NDA. AOD 9604 is the peripheral/lipolytic metabolic compound: β3-adrenergic receptor activation in adipose tissue, lipolysis promotion, with Phase 2 FDA data from the early 2000s. Positioning: cagrilintide for neuroendocrine satiety pathway and the post-GLP-1 amylin research wave; AOD 9604 for adipose lipolysis and GH-fragment metabolic research. The research buyer audience overlaps (both attract metabolic research interest) but the mechanistic stories are distinct, allowing natural co-cataloging without content duplication.
Key Takeaways
Research Takeaways
- AMY1R/AMY3R amylin receptor agonist — distinct from GLP-1R: Heterodimeric CTR/RAMP1 and CTR/RAMP3 complexes in area postrema/NTS/hypothalamus; completely different receptor family and anatomical distribution from incretin agonists; mechanistically additive.
- Phase 2 (Lancet 2021): 10.8% body weight reduction with cagrilintide 2.4mg monotherapy at 26 weeks; dose-dependent effect confirmed.
- REDEFINE 1 Phase 3 (n=3,417; 68 weeks): ~23% body weight reduction for CagriSema; 56.4% no longer obese; >20% lost ≥30% — strongest Phase 3 obesity data published as of April 2026.
- CagriSema NDA filed December 18, 2025: Not research-grade as of April 2026; expected decision late 2026–mid 2027. YPB.241 is RUO research-grade compound, not compound CagriSema.
- Non-fibrillating modification enables stable once-weekly formulation vs. pramlintide (3×/day); C-terminal lipidation → albumin binding → 159–195h half-life.
- Lipid chain handling note: Use low-protein-binding containers at low nanomolar research concentrations to prevent adsorption losses.
Business Takeaways
- ~95% Premier margin — highest-margin metabolic compound in the catalog.
- New/rising search volume growing fast post-REDEFINE results and December 2025 NDA; early content investment captures organic traffic as search volume scales.
- Only amylin/AMY receptor compound in YPB catalog — unique mechanism; no content overlap with any other metabolic guide.
- Cagrilintide + AOD 9604 + MOTS-c metabolic trio covers central amylin satiety (cagrilintide), peripheral lipolytic (AOD 9604), and mitochondrial AMPK (MOTS-c) — three mechanistically non-overlapping metabolic research tools from one buyer audience.
Ready to add cagrilintide to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”cagrilintide”]